Scholarlink

Purpose of Review <p>This review summarizes the emerging role of ultra-low temperature cryoablation (ULTC) in ventricular tachycardia (VT) ablation. It outlines the limitations of conventional techniques such as radiofrequency (RF) ablation and explores the current clinical data supporting ULTC’s deeper lesion formation, safety, and efficacy.</p> Recent Findings <p>ULTC delivers cryothermal energy at -140 to -150&#xa0;°C via a specialized catheter in a freeze–thaw–freeze sequence, achieving lesion depths ≥ 10&#xa0;mm. Clinical studies report &gt; 90% acute success, &gt; 60% VT-free survival, and &gt; 80% freedom from implantable cardioverter defibrillator (ICD) shocks at 6 months, with sustained effectiveness at 1-year follow-up. The approach is effective across both ischemic and non-ischemic cardiomyopathy without the need for adjunctive interventions. Ongoing preclinical work with augmented ULTC systems shows encouraging results.</p> Summary <p>ULTC offers a promising new strategy in VT ablation by creating durable, transmural lesions. Further randomized trials are warranted to confirm its long-term clinical benefits and safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The New Ice Age in Electrophysiology: Ultra-Low-Temperature Cryoablation for Ventricular Tachycardia

  • 期刊论文

  • 发表日期：

    2025年12月12日

查看全文
  • Vadivelu Ramalingam,
  • Elie Ganni,
  • Katia Dyrda,
  • Vidal Essebag,
  • Jacqueline Joza,
  • Atul Verma

摘要

Purpose of Review

This review summarizes the emerging role of ultra-low temperature cryoablation (ULTC) in ventricular tachycardia (VT) ablation. It outlines the limitations of conventional techniques such as radiofrequency (RF) ablation and explores the current clinical data supporting ULTC’s deeper lesion formation, safety, and efficacy.

Recent Findings

ULTC delivers cryothermal energy at -140 to -150 °C via a specialized catheter in a freeze–thaw–freeze sequence, achieving lesion depths ≥ 10 mm. Clinical studies report > 90% acute success, > 60% VT-free survival, and > 80% freedom from implantable cardioverter defibrillator (ICD) shocks at 6 months, with sustained effectiveness at 1-year follow-up. The approach is effective across both ischemic and non-ischemic cardiomyopathy without the need for adjunctive interventions. Ongoing preclinical work with augmented ULTC systems shows encouraging results.

Summary

ULTC offers a promising new strategy in VT ablation by creating durable, transmural lesions. Further randomized trials are warranted to confirm its long-term clinical benefits and safety.